Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00509899 · ClinicalTrials.gov registry record · Phase 1

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

A Phase 1 study of Myelofibrosis and Polycythemia Vera, sponsored by Incyte Corporation.

Completed
Registry status
Phase 1
Development phase
154
Enrollment target
2
Study locations

NCT00509899 is a Phase 1 study of Myelofibrosis and Polycythemia Vera that has completed, run by Incyte Corporation. The registered enrollment target is 154 participants, below the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target (20% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00509899, a Phase 1 study of Myelofibrosis and Polycythemia Vera, has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 1
Development phase
154 participants
Enrollment target
2
Study locations

Study Summary

To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).

Conditions Studied

Myelofibrosis Polycythemia Vera Thrombocytosis

Interventions

  • DRUG Ruxolitinib

Study Locations (2)

Minnesota

  • - Rochester

Texas

  • - Houston

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2007-06
Est. Completion 2017-02
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00509899

The ClinicalTrials.gov registry entry for NCT00509899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target (20% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.

NCT00509899 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Texas.

Frequently Asked Questions

What is clinical trial NCT00509899 about?

NCT00509899 is a clinical study titled "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis". To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).

What is the current status of trial NCT00509899?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2007-06. Estimated completion is 2017-02.

What conditions does trial NCT00509899 study?

This clinical trial studies the following conditions: Myelofibrosis, Polycythemia Vera, Thrombocytosis.

What interventions are being tested in trial NCT00509899?

The interventions under investigation include: Ruxolitinib (DRUG).

Who is sponsoring clinical trial NCT00509899?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00509899 being conducted?

This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelofibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelofibrosis

All registered trials for this condition

Polycythemia Vera

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.